Jennifer C. Chen, MPH

Senior Project Portfolio Manager, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Ms. Chen joined the team in 2017. She focuses on an array of drug pricing-related analyses, with her current projects analyzing the supply chain dynamics and regulatory processes in the US and abroad, profiling Medicare Part D formularies, and critically reviewing key industry talking points. She also oversees day-to-day operations of program grants.

Prior to drug pricing, Ms. Chen supported the Epidemiology Service at Memorial Sloan Kettering Cancer Center on projects specific to the cost-effectiveness analyses of colorectal cancer screening. She holds an MPH in epidemiology and pharmaceuticals management from Boston University School of Public Health, and a BS in anthropology from the University of California, Riverside.

Focus Areas

Supply chain dynamics
Formulary analyses
Drug pricing
Connect

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013
Fact Checking the NYT Fact Check on the Trump Proposal
The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.
Drug Pricing Lab

Meet the Rest of the Team

The Drug Pricing Lab’s team brings together tremendous experience in medicine, economics, consulting, sociology, and finance.
Meet the Team
Newsletter

Stay up to date on our work and news